125 related articles for article (PubMed ID: 2236173)
1. The biological basis for interleukin-2 anticancer therapy.
Silver HK; Klasa RJ
Prog Clin Biol Res; 1990; 354B():37-52. PubMed ID: 2236173
[No Abstract] [Full Text] [Related]
2. Interleukin 2 in cancer therapy.
Testa U; Montesoro E; Bulgarini D; Samoggia P; Masciulli R; Habetswallner D; Carè A; Mariani G; Giannella G; Boccoli G
Ann Ist Super Sanita; 1990; 26(3-4):283-334. PubMed ID: 2091501
[TBL] [Abstract][Full Text] [Related]
3. Studies of the immunological effects of interleukin-2 in patients with bladder cancer and renal cell carcinoma.
Hermann GG
APMIS Suppl; 1993; 35():1-26. PubMed ID: 8251200
[No Abstract] [Full Text] [Related]
4. Therapy with interleukin-2 and tumor-derived activated lymphocytes.
Oldham RK
Immunol Ser; 1994; 61():251-71. PubMed ID: 8011748
[No Abstract] [Full Text] [Related]
5. [Cancer of the kidney in adults. Treatment of the metastatic stage].
Prog Urol; 1997 Nov; 7(5):879-95. PubMed ID: 9458484
[No Abstract] [Full Text] [Related]
6. Cure of B16F10 melanoma lung metastasis in mice by chronic indomethacin therapy combined with repeated rounds of interleukin 2: characteristics of killer cells generated in situ.
Lala PK; Parhar RS
Cancer Res; 1988 Mar; 48(5):1072-9. PubMed ID: 3124954
[TBL] [Abstract][Full Text] [Related]
7. Tumor-infiltrating lymphocytes from human solid tumors: antigen-specific killer T lymphocytes of activated natural killer lymphocytes.
Whiteside TL; Heo DS; Takagi S; Herberman RB
Immunol Ser; 1989; 48():139-57. PubMed ID: 2488318
[No Abstract] [Full Text] [Related]
8. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P
In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491
[TBL] [Abstract][Full Text] [Related]
9. [Immunotherapy of malignant melanoma].
Flageul B; Miclea JM; Bensussan A; Degos L
Pathol Biol (Paris); 1990 Oct; 38(8):881-2. PubMed ID: 2274397
[No Abstract] [Full Text] [Related]
10. Tumor-derived activated cells: culture conditions and characterization.
Maleckar JR; Friddell CS; Lewko WM; Yannelli JR; West WH; Oldham RK
Immunol Ser; 1989; 48():159-73. PubMed ID: 2488319
[No Abstract] [Full Text] [Related]
11. Interleukin-2, killer cells and cancer therapy: an overview.
Parkinson DR; Lotzová E
Nat Immun Cell Growth Regul; 1990; 9(4):237-41. PubMed ID: 2215512
[No Abstract] [Full Text] [Related]
12. Combination biologic therapy with interleukin-2 and interferon-alfa in the outpatient treatment of metastatic renal cell carcinoma.
Figlin RA; Pierce WC; Belldegrun A
Semin Oncol; 1993 Dec; 20(6 Suppl 9):11-5. PubMed ID: 8284686
[No Abstract] [Full Text] [Related]
13. Adoptive cellular immunotherapy of cancer.
Winter H; Fox BA
Curr Opin Mol Ther; 1999 Feb; 1(1):89-97. PubMed ID: 11249690
[No Abstract] [Full Text] [Related]
14. Evidence for local and systemic activation of immune cells by peritumoral injections of interleukin 2 in patients with advanced squamous cell carcinoma of the head and neck.
Whiteside TL; Letessier E; Hirabayashi H; Vitolo D; Bryant J; Barnes L; Snyderman C; Johnson JT; Myers E; Herberman RB
Cancer Res; 1993 Dec; 53(23):5654-62. PubMed ID: 8242620
[TBL] [Abstract][Full Text] [Related]
15. Repetitive weekly cycles of interleukin 2: effect of outpatient treatment with a lower dose of interleukin 2 on non-major histocompatibility complex-restricted killer activity.
Goldstein D; Sosman JA; Hank JA; Weil-Hillman G; Moore KH; Borchert A; Bechhofer R; Storer B; Kohler PC; Levitt D
Cancer Res; 1989 Dec; 49(23):6832-9. PubMed ID: 2819723
[TBL] [Abstract][Full Text] [Related]
16. Studies on lymphokine activated killer cells in the rat: analysis of precursor and effector cell phenotype and relationship to natural killer cells.
Hiserodt JC; Vujanovic NL; Reynolds CW; Herberman RB; Cramer DV
Prog Clin Biol Res; 1987; 244():137-46. PubMed ID: 2958869
[No Abstract] [Full Text] [Related]
17. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T
Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715
[TBL] [Abstract][Full Text] [Related]
18. The cellular and molecular basis of natural antitumor immunity in renal cell carcinoma patients.
Schendel DJ; Falk CS; Frankenberger B; Noessner E; Schleypen J; Pohla H
Urologe A; 2004 Sep; 43 Suppl 3():S133-5. PubMed ID: 15179552
[No Abstract] [Full Text] [Related]
19. [Adoptive immunotherapy with interleukin-2 and with interleukin-2 activated lymphocytes].
Eggermont AM; Stoter G; Jansen RL; Bolhuis RL
Ned Tijdschr Geneeskd; 1989 Jul; 133(28):1387-92. PubMed ID: 2677757
[No Abstract] [Full Text] [Related]
20. Interleukin-2: its rationale and role in the treatment of patients with cancer.
Rubin JT
Cancer Treat Res; 1995; 80():83-105. PubMed ID: 8821575
[No Abstract] [Full Text] [Related]
[Next] [New Search]
